Robb Gary Charles's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Aug 18, 2026
- Accession no.
- 0001193125-26-355560
- Filed
- Aug 18, 2026, 4:30 PM ET
- Trade date
- Aug 17, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $1.16M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Robb Gary CharlesCIK 0001529655 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Common Stock | GGiftDisposed | −125 | $0.00 | $0 | 13,426 | Direct | |
| Aug 17, 2026 | Common Stock | SSaleDisposed | −10,000 | $116.26F2 | −$1,162,572 | 39,716 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.00 to $116.54 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.